TRAW · XBRL financial data

Traws Pharma financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (TRAW's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY24Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	57	56*	56	57	57	56*	57	2,733	0*	0*	—	—
Revenue from contracts with customers	57	—	—	—	57	—	—	—	—	—	—	—
Research and development	2,460	2,434*	1,912	—	—	—	2,506	2,291	—	—	4,912	1,101
General and administrative	2,686	2,084*	3,356	1,977	3,480	3,476*	2,754	1,691	1,744	2,333*	2,034	3,479
Total operating expenses	5,146	4,518*	5,268	123,405	8,593	5,334*	5,260	3,982	4,055	7,368*	6,946	3,175
Operating income (loss)	(5,089)	(4,462)*	(5,212)	(123,348)	(8,536)	(5,278)*	(5,203)	(1,249)	(4,055)	(7,368)*	(6,946)	(3,175)
Interest income	—	year only	—	—	—	year only	—	—	—	year only	—	—
Other income (expense)	350	278*	229	205	61	(206)*	180	188	96	14*	(2)	(94)
Net income (loss)	(4,739)	(4,184)*	(4,983)	(123,143)	(8,475)	(29,922)*	21,490	(915)	(3,962)	(7,443)*	(7,107)	(3,054)
Earnings per share, basic‡ USD per share	(5.75)	(5.00)*	(6.00)	(121.75)	(8.81)	—	2.17	(0.11)	(0.34)	—	(0.53)	(0.16)
Earnings per share, diluted‡ USD per share	(5.75)	(5.00)*	(6.00)	(121.75)	(8.81)	—	2.09	(0.11)	(0.34)	—	(0.53)	(0.16)
Weighted average shares, basic‡ thousands of shares	840	840*	842	1,012	962	—	6,966	5,821	8,819	—	10,641	15,864
Weighted average shares, diluted‡ thousands of shares	840	840*	842	1,012	962	—	7,215	5,821	8,819	—	10,641	15,864

‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (September 2024); filings made before it reported them unadjusted.
† Share count changed about 3x in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (TRAW's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY24Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	25,244	20,559	16,390	16,886	5,410	21,338	15,937	13,081	6,420	3,820	3,133	5,016
Prepaid and other current assets	1,749	1,821	1,745	1,767	1,392	1,848	1,265	966	1,214	365	845	553
Total current assets	27,011	22,660	18,153	18,671	8,923	24,951	18,856	15,370	9,625	7,979	5,665	9,023
Property and equipment, net	26	22	18	14	12	10	9	8	7	7	6	5
Total assets	27,038	22,683	18,172	18,686	8,936	24,962	19,063	15,622	12,443	10,617	8,156	11,470
Accounts payable	6,148	5,619	6,568	6,174	5,472	8,186	7,656	4,759	5,105	5,653	7,665	6,334
Accrued liabilities	3,300	3,375	2,628	3,509	2,650	3,121	2,519	2,593	2,782	5,493	5,543	3,401
Total current liabilities	9,674	9,220	9,422	9,910	8,348	11,533	10,401	7,352	7,887	11,146	13,208	9,735
Total liabilities	12,521	12,011	12,157	12,587	10,969	56,592	13,063	7,360	7,898	11,246	13,467	9,779
Accumulated deficit	(478,447)	(482,631)	(487,614)	(610,757)	(619,232)	(649,154)	(627,664)	(628,579)	(632,541)	(639,984)	(647,091)	(650,145)
Total liabilities and equity	27,038	22,683	18,172	18,686	8,936	24,962	19,063	15,622	12,443	10,617	8,156	11,470
Common shares outstanding (cover page)‡ thousands of shares	840	842	1,012	1,012	3,026	5,074	5,564	7,064	7,991	10,157	15,151	15,368

‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (September 2024); filings made before it reported them unadjusted.
† Share count changed about 3x in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (TRAW's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY24Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(4,739)	(4,184)*	(4,983)	(123,143)	(8,475)	(29,922)*	21,490	(915)	(3,962)	(7,443)*	(7,107)	(3,054)
Stock-based compensation	360*	332*	333	380*	343*	334*	161	105*	135*	327*	634	816*
Depreciation and amortization	5*	4*	4	4*	2*	2*	1	1*	15*	44*	44	44*
Net cash from operating activities	(4,469)*	(4,430)*	(4,424)	(9,852)*	(11,476)*	(4,040)*	(5,437)	(5,979)*	(4,011)*	(2,758)*	(2,576)	(7,504)*
Purchases of property and equipment	—	0*	—	—	—	—	—	—	—	—	—	—
Net cash from investing activities	—	0*	—	—	0*	0*	—	—	—	0*	—	—
Proceeds from issuing common stock	—	—	—	—	0*	—	122	3,257*	116*	2,087*	1,897	120*
Net cash from financing activities	—	—	—	—	0*	19,977*	13	3,095*	(62)*	158*	1,897	9,390*
Net change in cash	(4,485)*	(4,423)*	(4,431)	496*	(11,476)*	15,928*	(5,401)	(2,856)*	(6,661)*	(2,600)*	(687)	1,883*

† Share count changed about 3x in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Mannatech	6,034	26,650	(792)*	1.9M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
LeonaBio	32,323	not reported	(16,958)*	9.4M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Alaunos Therapeutics	124	0	(300)*	2.5M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Raphael Pharmaceutical	1	not reported	0*	20.2M	—	Q2 FY26 10-QJun 30, 2026
Scienture Holdings	8,188	344	(3,132)*	41.1M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Bioxytran	177	not reported	(350)*	114.7M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Artelo Biosciences	4,198	not reported	(5,033)*	4.6M	0.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.